Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled trial of INCB000928 in fibrodysplasia ossificans progressiva
2021-002286-17Phase 2Active
- Sponsor
- Incyte
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in fibrodysplasia ossificans progressiva (FOP) comparing INCB000928 with Placebo (2 arms). Primary endpoint: Total volume of new heterotopic ossification at Week 24. Started Oct 2021; status: active.
02
Drugs
zilurgisertib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2021-002286-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002286-17.